



Vivendy Therapeutics Ltd. signs exclusive Patent Licensing Agreement for the development of an Enzyme Replacement Therapy for Morbus Morquio

July 7 2008, Saint Louis University, Office of Innovation and Intellectual Property, St. Louis, Missouri, USA and Vivendy Therapeutics Ltd., Basel, Switzerland finalized and signed a License Agreement where Saint Louis University granted to Vivendy Therapeutics the exclusive license to use its patents* for the research, development, manufacturing, marketing, sales and other use of the licensed products in the field of Enzyme Replacement Therapy (ERT) compositions intended for the treatment of patients having mucopolysaccharidosis IVA (MPS IVA).

Vivendy Therapeutics Ltd. is a pharmaceutical company that is developing an enzyme replacement therapy (ERT) for *Morbus Morquio* (Mucopolysaccharidosis (MPS) IVA), a rare lysosomal storage disease. This disease is caused through the deficient activity of N-acetylgalactosamine-6-sulfatase (GALNS) leading to lysosomal storage of glycosaminoglycans such as Keratan Sulfate (KS) and Chondroitin-6-Sulfate (C6S).

Today, there is no therapy for MPS IVA in place. With the license on the IP of the Saint Louis University, Vivendy can access a recombinant human GALNS enzyme, that is specifically modified - enhancing the efficacy of the therapy in MPS IVA significantly. Compared to the native enzyme the modification maximizes the delivery of the enzyme to clear the storage materials efficiently. In addition to the IP, Vivendy also licensed the Morquio Mouse model, the specific GALNS antibodies and the access to the tremendous know-how on *Morbus Morquio*, so that Vivendy is able to develop an effective ERT for MPS IVA with the best enzyme for the patients.

Maurice Foxworth, Director, Office of Innovation & IP; Saint Louis University adds:” We are very confident that Vivendy Therapeutics – given their enormous know-how in clinical development, enzyme production and registration - will use their access to our IP,

Animal Model and antibodies in the best possible way to help MPS IVA patients”.

The license agreement includes the right to grant a sublicense to third parties and the access to MPS IVA mice and the Morquio Mouse models, monoclonal antibodies for GALNS, cell lines producing the modified GALNS enzyme as well as confidential information (know how) for the development of an ERT for the treatment of Morbus Morquio type A (MPS IVA).

*** Information for the editor:**

The exact patent identification is as follows: patent App. No. PCT/JP2005/010760 (Pub. No. WO 2005/121344), App. No. US 10/864,758 (Pub. No. US 2005/0276796), App. No. JP 2006-545832 (Pub. No. JP 2008-501307); and App. No. EP 2005 0748127 (Pub. No. EP 1 766 024) as well as all related patent applications filed or owned by Saint Louis University

About Saint Louis University

Established in the United States in 1836, Saint Louis University School of Medicine has the distinction of awarding the first medical degree in the western part of the United States. The school educates physicians and biomedical scientists, conducts medical research, and provides health care on a local, national and international level. Research at the school seeks new cures and treatments in five key areas: cancer, liver disease, heart/lung disease, aging and brain disease, and infectious disease.

About Vivendy Therapeutics Ltd.

Vivendy Therapeutics was founded in March 2006, as a spin-off of Inotech Biotechnologies AG. The company's mission is the development of an enzyme replacement therapy (ERT) for Morbus Morquio (Mucopolysaccharidosis - MPS IVA), a rare lysosomal storage disease, based on a gene deficiency with an incidence of 1 to 200 000 live births. MPS IVA represents 5% of the lysosomal storage disorders (LSDs). More information at www.vivendy.ch

Contact address:

Dr. Roland Toder, CEO

Vivendy Therapeutics Ltd.

Peter Merian Str. 45

CH-4052 Basel

Switzerland

T: +41 61 271 8780

E: toder@vivendy.ch

www.vivendy.ch

Disclaimer

This press release does not constitute or form part, or all, of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall part, or all, of these materials or their distribution from the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. This press release contains forward-looking statements based on the currently held beliefs and assumptions of the management of Vivendy, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and

unknown risks, uncertainties and other factors, which may cause the actual results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on these forward-looking statements. Vivendy disclaims any obligation to update these forward-looking statements to reflect future events or developments.